Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.
The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.
The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.
Malaysia needs Russia's assistance in maintaining and repairing Su-30MKM fighter jets
Japanese Prime Minister Shinzo Abe said that US army bases will not appear on the southern Kuril Islands in the even Russia delivers them to Japan
Posters for the play "Adam and Eve. Life after Paradise" with pictures of dancers Arsen Aghamalyan and Oksana Vasilyeva were banned in the city of Tver, Central Russia